Strontium ranelate effect on bone mineral density is modified by previous bisphosphonate treatment

BRUN LR; GALICH AM; VEGA E; SALERNI H; MAFFEI L; PREMROU V; COSTANZO PR; SARLI MA; REY P; LARROUDÉ MS; MOGGIA MS; BRANCE ML; SÁNCHEZ A

SpringerPlus

Springer

Año: 2014

The aim of this study was evaluate the effect of strontium ranelate (SrR) on bone mineral density (BMD) and bone turnover markers after 1 year of treatment. Additionally, the effect of SrR in bisphosphonates-naïve patients (BP-naïve) compared to patients previously treated with bisphosphonates (BP-prior) was analyzed. This retrospective study included 482 postmenopausal women treated with SrR (2 g/day) for 1 year in ten Argentine centers; 41 patients were excluded due to insufficient data, while 441 were included. Participants were divided according to previous bisphosphonate treatment in two groups: BP-naïve (n= 87) and BP-prior (n= 350). Data are expressed as mean±SEM. After 1 year of treatment with SrR the bone formation markers total alkaline phosphatase and osteocalcin were increased (p<0.0001), while the bone resorption marker s-CTX was decreased (p= 0.0579). Also increases in BMD at the lumbar spine (LS, 3.73%), femoral neck (FN, 2.00%) and total hip (TH, 1.54%) [p<0.0001] were observed. These increments were significant (p<0.0001) both among BP-naïve and BP-prior patients. Interestingly, the change in BMD after 1 year of SrR treatment was higher in BP-naïve patients: LS: BP-naïve= 4.58±0.62%; BP-prior= 3.45±0.28% (p= 0.078). FN: BP-naïve= 2.79±0.56%; BP-prior= 2.13±0.29% (p= 0.161). TH: BP-naïve= 3.01±0.55%; BP-prior= 1.22±0.27% (p=0.0006). SrR treatment increased BMD and bone formation markers and decreased a bone resorption marker in the whole group, with better response in BP-naïve patients.